{"nctId":"NCT00554229","briefTitle":"A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases","startDateStruct":{"date":"2007-11"},"conditions":["Prostate Cancer"],"count":896,"armGroups":[{"label":"ZD4054","type":"EXPERIMENTAL","interventionNames":["Drug: ZD4054"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ZD4054","otherNames":["Zibotentan"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients who answer TRUE to the following criteria may be eligible to participate in this trial.\n\n1. Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone metastases)\n2. Increasing Prostate Specific Antigen (PSA) over a one month period\n3. No pain, or mild pain from prostate cancer\n4. Currently receiving treatment with surgical or medical castration\n\nExclusion Criteria:\n\nPatients who answer TRUE to the following may NOT eligible to participate in this trial.\n\n1. Currently using opiates based pain killers)\n2. Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone)\n3. Suffering from heart failure or had a myocardial infarction within last 6 months\n4. A history of epilepsy or seizures","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Median time (in months) from randomisation until death using the Kaplan-Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"Median time (in months) from randomisation until clinical progression of disease, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline, using the Kaplan-Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Use of Opiates","description":"Median time (in months) from randomisation until use of opiates for disease-related symptoms for a duration ≥1 week using the Kaplan-Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Skeletal Related Events","description":"Median time (in months) from randomisation until occurrence of a skeletal related event, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression, using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Metastases Formation","description":"Median time (in months) from randomisation to appearance of ≥4 new bone lesions using the Kaplan-Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life","description":"Median time (in months) from randomisation until deterioration of Health related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Prostate-specific Antigen (PSA) Progression","description":"Median time (in months) from randomisation to first PSA value \\>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Progression","description":"Median time (in months) from randomisation to first assessment of an increased pain event, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Initiation of Chemotherapy","description":"Median time (in months) from randomisation to first administration of any chemotherapy using the Kaplan-Meier method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic Characteristics of ZD4054","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":98,"n":298},"commonTop":["Oedema Peripheral","Headache","Constipation","Fatigue","Nausea"]}}}